MAOB Antibodies

Structure of MAOB

MAOB (monoamine oxidase B) is a flavin protease with a molecular weight of approximately 58-60 kDa. Its precise molecular weight varies slightly among different species due to differences in amino acid sequences.

This protein is composed of approximately 520 amino acids, and its tertiary structure forms a typical flavin binding domain and substrate binding cavity. The active center of MAOB covalently binds to a FAD covalent group, which is the core of its catalytic monoamine oxidation reaction. The enzyme protein presents as a dimer form on the outer mitochondrial membrane, with its secondary structure composed of interlaced α -helices and β -folds, jointly enclosing hydrophobic substrate channels. The conserved amino acids at the entrance of the channel are responsible for recognizing substrates such as phenylethylamine, while FAD cofactors achieve the dehydrogenation process of amines through reversible REDOX cycles.

Fig. 1 Overall structure of human MAOB.¹

Key structural properties of MAOB:

• Lutein-dependent dimer configuration
• Hydrophobic substrate channel
• FAD coenzyme-dependent REDOX system

Functions of MAOB

The monoamine oxidase B encoded by the MAOB gene mainly undertakes the metabolic regulation of monoamine neurotransmitters in the nervous system, and simultaneously participates in the regulation of various physiological and pathological processes:

The kinetic characteristics of this enzyme are characterized by high affinity for phenylethylamine, and its substrate selectivity curve contrasts sharply with that of MAOA. This difference is precisely an important structural basis for the development of targeted drugs for Parkinson's disease (such as selegilan).

Applications of MAOB and MAOB Antibody in Literature

1. Nam, Min-Ho, et al. "Revisiting the role of astrocytic MAOB in Parkinson's disease." International journal of molecular sciences 23.8 (2022): 4453. https://doi.org/10.3390/ijms23084453

The article indicates that the traditional view holds that MAOB degrades dopamine, but research has found that its actual function is to catalyze the abnormal synthesis of GABA and hydrogen peroxide by astrocytes. The former inhibits the activity of dopamine neurons, while the latter exacerbates neural degeneration. New MAOB inhibitors can improve Parkinson's symptoms by reversing this process.

2. Tian, Zhen, et al. "Inhibition of MAOB ameliorated high-fat-diet-induced atherosclerosis by inhibiting endothelial dysfunction and modulating gut microbiota." Nutrients 15.11 (2023): 2542. https://doi.org/10.3390/nu15112542

This study reveals that under a high-fat diet, the expression of monoamine oxidase B (MAOB) in vascular endothelial cells increases, which is a new source of cardiovascular reactive oxygen species (ROS). MAOB promotes atherosclerosis by inducing oxidative stress and causing endothelial dysfunction. Further research has found that the inhibitor selegilan can exert anti-atherosclerotic effects by improving endothelial function and regulating the intestinal flora.

3. Huang, Hsiang‐Ching, et al. "MAOB expression correlates with a favourable prognosis in prostate cancer, and its genetic variants are associated with the metastasis of the disease." Journal of Cellular and Molecular Medicine 28.8 (2024): e18229. https://doi.org/10.1111/jcmm.18229

This study reveals that MAOB plays a tumor suppressor role in prostate cancer, and its expression level is negatively correlated with the malignancy of the tumor and poor prognosis. Genetic analysis of the population in Taiwan, China, has found that specific genetic variations of MAOB (rs3027452, rs1799836) are significantly associated with the risk of cancer metastasis. Functional experiments have confirmed that MAOB can inhibit the proliferation and migration ability of cancer cells.

4. Tabata, Yuki. "Geranylgeranoic acid and the MAOB–CYP3A4 axis: a metabolic shift underlying age-related liver cancer risk." Frontiers in Aging 6 (2025): 1680031. https://doi.org/10.3389/fragi.2025.1680031

Research has found that monoamine oxidase B (MAOB) is a key enzyme for the synthesis of geranoate (GGA) in the body, and its activity decreases with aging, which may increase the risk of liver cancer. When MAOB activity is insufficient, cytochrome P450 3A4 (CYP3A4) can provide a compensatory synthetic pathway. This MABO-CYP3A4 axis mechanism provides a new perspective for understanding liver aging and developing related prevention strategies.

5. Tabata, Yuki, and Yoshihiro Shidoji. "Hepatic CYP3A4 enzyme compensatively maintains endogenous geranylgeranoic acid levels in MAOB-knockout human hepatoma cells." Metabolites 12.2 (2022): 140. https://doi.org/10.3390/metabo12020140

This study confirmed that in liver cancer cells, MAOB is the key enzyme that catalyzes the oxidation of GGOH to GGA precursors. However, after the knockout of the MAOB gene, cytochrome P450 3A4 (CYP3A4) is upregulated and acts as a substitute enzyme to perform the same function, thereby maintaining endogenous GGA levels. This indicates that the biosynthesis of GGA is maintained by multiple enzymes together.

Creative Biolabs: MAOB Antibodies for Research

Creative Biolabs specializes in the production of high-quality MAOB antibodies for research and industrial applications. Our portfolio includes monoclonal antibodies tailored for ELISA, Flow Cytometry, Western blot, immunohistochemistry, and other diagnostic methodologies.

• Custom MAOB Antibody Development: Tailor-made solutions to meet specific research requirements.
• Bulk Production: Large-scale antibody manufacturing for industry partners.
• Technical Support: Expert consultation for protocol optimization and troubleshooting.
• Aliquoting Services: Conveniently sized aliquots for long-term storage and consistent experimental outcomes.

For more details on our MAOB antibodies, custom preparations, or technical support, contact us at email.